Alataby Harith, Atemnkeng Francis, Bains Sandeep S, Kenne Foma M, Diaz Keith, Nfonoyim Jay
Department of Medicine, Richmond University Medical Center, Staten Island, NY 10310, USA.
J Med Cases. 2020 Dec;11(12):403-406. doi: 10.14740/jmc3588. Epub 2020 Oct 21.
There has been increasing evidence of co-infections with coronavirus disease 2019 (COVID-19) pneumonia, which increases the severity of the disease. Organisms such as and have been previously isolated. We present a case of a COVID-19 patient treated with baricitinib and dexamethasone who later developed -carbapenem-resistant Enterobacteriaceae (CRE) and bloodstream infections, treated with meropenem/vaborbactam and micafungin, respectively. These infections are exceedingly rare and are mostly reported in immunosuppressed patients. The finding of these bloodstream infections raises concerns on the cause of immunosuppression in this patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) treated with baricitinib and dexamethasone. There has been no report so far of COVID-19 associated with these co-infections.
越来越多的证据表明，2019冠状病毒病（COVID-19）肺炎存在合并感染，这会增加疾病的严重程度。此前已分离出如[未提及具体微生物名称]等微生物。我们报告一例COVID-19患者，该患者接受巴瑞替尼和地塞米松治疗，后来分别发生了耐碳青霉烯类肠杆菌科细菌（CRE）和[未提及具体微生物名称]血流感染，分别接受美罗培南/瓦博巴坦和米卡芬净治疗。这些感染极其罕见，大多在免疫抑制患者中报道。这些血流感染的发现引发了对该接受巴瑞替尼和地塞米松治疗的感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者免疫抑制原因的关注。迄今为止，尚无COVID-19与这些合并感染相关的报告。
